genIC (24IM) Performance Measures Project Request for genIC Approval (for data collection in 2023, 2024, 2025)

OMB Control Number 0920-1282
Performance Measures Project
Request for genIC Approval (for data collection in 2023, 2024, 2025)
CIO: National Center for Injury Prevention and Control, Division of Overdose Prevention, State Program
implementation Branch
PROJECT TITLE: Performance Measures Reporting for OD2A in States Cooperative Agreement
PURPOSE AND USE OF COLLECTION: As one of CDC’s primary overdose prevention initiatives, the
Overdose Data to Action program occupies a unique niche within the larger scope of Health and Human
Services’ (HHS) drug overdose initiatives, including the HHS Overdose Prevention Strategy (OPS). This
request is to initiate performance measures data collection activities for the Overdose Data to Action in
State (OD2A-S) cooperative agreement. To better understand the implementation successes and
barriers as well as outcomes of OD2A-S prevention interventions, CDC developed a set of standard
performance measures to be reported by all OD2A-S recipients. The primary goal of performance
measures in OD2A-S is to provide a common set of indicators that will be used by OD2A-S recipients and
their partners, as well as by CDC, to monitor progress and identify areas for improvement. It is
important to note, OD2A-S has a complementary cooperative agreement. OD2A: Limiting Overdose
through Collaborative Actions in Localities (OD2A: LOCAL) works with city, county, and territory health
department recipients. Together OD2A-S and OD2A: LOCAL are the two primary overdose cooperative
agreements for CDC’s overdose prevention initiatives.
NUMBER AND TITLE OF NOFO: Overdose Data to Action in States (OD2A-S) CDC-RFA-CE-23-0002
NUMBER OF PARTICIPATING RECIPIENTS: 50
DESCRIPTION OF NOFO (check all that apply):
_

Funds all 50 states

_X_

Has budget higher than $10 million per year

_X_

Has significant stakeholder interest (e.g. partners, Congress)

Please elaborate:
In response to the growing severity of the opioid overdose epidemic, the US government declared the
opioid overdose epidemic a public health emergency on October 26, 2017, joining at least eight states
that had declared the opioid overdose epidemic a statewide emergency. U.S. drug overdose deaths have
increased to historic levels in recent years, with nearly 108,000 deaths occurring in 2022. In 2022, drug
overdose deaths involving any opioids accounted for more than three-fourths of all drug overdose
deaths. Drug overdose deaths involving cocaine or psychostimulants with abuse potential—such as
1

methamphetamine—accounted for more than one-fourth and nearly two-thirds, respectively, of drug
overdose deaths overall during 2022.
The drug overdose epidemic is one of the U.S. Department of Health and Human Services (HHS) top
priorities. In 2017, HHS launched a 5-point Opioid Strategy: 1) Access: Better Prevention, Treatment, and
Recovery Services, 2) Data: Better Data on the Epidemic, 3) Pain: Better Pain Management, 4)
Overdoses: Better Targeting of Overdose-Reversing Drugs, and 5) Research: Better Research on Pain and
Addiction. The current HHS Overdose Prevention Strategy (OPS) includes four broad domains: 1) Primary
Prevention, 2) Harm Reduction, 3) Evidence-based Treatment, and 4) Recovery Support. Striving to
address HHS OPS domains, CDC’s Division of Overdose Prevention (DOP) has a comprehensive portfolio
of overdose surveillance and prevention efforts, including its flagship Overdose Data to Action (OD2A)
cooperative agreements (CoAgs). OD2A in States (OD2A-S), focuses on overdose surveillance and
prevention efforts by city, county, and territory health departments.
PERFORMANCE METRICS USED & JUSTIFICATIONS:
The purpose of the OD2A-S is to support funded health departments to use data to drive action steps to
reduce overdose morbidity and mortality as fast as possible, with a primary focus on opioid, stimulant,
and polysubstance use involving opioids and/or stimulants. These action steps should address health
disparities and inform prevention and response efforts. Information collected will provide crucial data
for program performance monitoring, and program success. These performance measures were
designed in collaboration with CDC subject matter experts, OD2A-S recipients, and other selected
experts. Data collection will include 100% of jurisdictions funded in the OD2A-S NOFO. Data will be
analyzed using descriptive and summary statistics, and qualitative summaries. These standardized
performance measures will be used to help:
1) Recipients show progress and communicate progress to their health department leadership.
2) CDC and recipients inform future CDC programmatic investments.
3) CDC and recipients understand the contributions of OD2A-S across overdose prevention
strategies and use data for programmatic improvement.
4) CDC communicates with Health and Human Services (HHS) and other federal policymakers
about the progress made under OD2A-S.
Additionally, these performance measures are committed to addressing equitable delivery of and
improved access to care and services for people who use drugs (PWUD) and other populations of focus.
Performance measures also can endeavor to address the needs of populations of focus, noting the
intersectionality and interconnectedness across sociodemographic characteristics (e.g., people
experiencing homelessness, people who are incarcerated, race, ethnicity, LGBTQIA+) and the
communities in which populations of focus live. Performance measures can reveal health disparities in
overdose prevention, treatment, and recovery efforts among disproportionately affected communities
that may be defined geographically and/or socio-demographically, including but not limited to
communities affected by high rates of opioid prescribing, overdose morbidity, overdose mortality, or
naloxone administration.
There are 8 performance measures. There are 7 quantitative measures (see AttB_OD2AS Excel Reporting
Tool and AttC_OD2AS Partners Portal PM Module Screenshots) and 1 qualitative measure (see
AttA_OD2AS PM Technical Guidance and OD2AS Partners Portal PM Module Screenshots). OD2A
2

recipients are expected to report on all performance measures on an annual basis. This does not limit
what individual OD2A-S health departments want to capture for their use, and individual recipients can
examine their capacities to collect, analyze, and disseminate additional performance measure data.
CERTIFICATION:
I certify the following to be true:
1. The collection is non-controversial and does not raise issues of concern to other federal agencies.
2. Information gathered is meant primarily for program improvement and accountability; it is not
intended to be used as the principal basis for policy decisions.
Name:

Adrienne Herron, PhD
To assist review, please answer the following questions:
ANNUALIZED BURDEN HOURS
This table calculates the total estimated burden per year for all recipients.
Type of Respondent

Form Name

No. of

No. of Responses

Avg. Burden Per

Total

Respondents

per Respondent

Response

Annualized
Burden
Hours

OD2AS_PM
Technical
OD2A-State health
departments

Guidance (see

50

1

20

1000

50

1

15

750

AttA)
OD2AS_Excel
Reporting Tool
(see AttB)

Totals

1750

TOTAL BURDEN HOURS FOR THIS GENIC
This table specifies the calendar years in which information will be collected and calculates the total
burden hours requested over the approved timeframe of the generic.

3

Data Collection Timeframe (List up to 3 Years)

No. Years

Annualized

Total Burden Hours

Requested

Burden Hours

for this GENIC

2024,2025,2026

3

1750

FEDERAL COST: The estimated annual cost to the Federal government is $161,963
Administration of the Instrument
1. How will you collect the information? (Check all that apply)
[ X] Web-based
[ ] Email
[ ] Postal Mail
[ X ] Other, Explain Excel Reporting Tool
Please make sure all instruments, instructions, and scripts are submitted with the request.
Attachments
A. OD2AS_PM Technical Guidance
B. OD2AS_Excel Reporting Tool
C. OD2AS_Partners Portal PM Module Screenshots

4

5250